These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27377469)

  • 41. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
    Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippmann SM; Parnes HL; Dluzniewski PJ; Isaacs WB; De Marzo AM; Drake CG; Platz EA
    Prostate; 2015 Sep; 75(13):1403-18. PubMed ID: 26047319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility.
    Huang WJ; Wu LJ; Min ZC; Xu LT; Guo CM; Chen ZP; Lou XJ; Xu B; Lv BD
    Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
    Jurečeková J; Drobková H; Šarlinová M; Babušíková E; Sivoňová MK; Matáková T; Kliment J; Halašová E
    Anticancer Res; 2018 Jun; 38(6):3663-3667. PubMed ID: 29848725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
    Mandal RK; Gangwar R; Mandhani A; Mittal RD
    DNA Cell Biol; 2010 Apr; 29(4):183-90. PubMed ID: 20070155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
    Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study.
    Zheng SL; Augustsson-Bälter K; Chang B; Hedelin M; Li L; Adami HO; Bensen J; Li G; Johnasson JE; Turner AR; Adams TS; Meyers DA; Isaacs WB; Xu J; Grönberg H
    Cancer Res; 2004 Apr; 64(8):2918-22. PubMed ID: 15087412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer.
    Martinez-Fierro ML; Garza-Veloz I; Rojas-Martinez A; Ortiz-Lopez R; Castruita-de la Rosa C; Ortiz-Castro Y; Lazalde-Ramos BP; Cervantes-Villagrana AR; Castañeda-Lopez ME; Gomez-Guerra L; Delgado-Enciso I; Martinez-Torres AA
    Cancer Biomark; 2013; 13(4):235-41. PubMed ID: 24240584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD24 gene polymorphism--a novel prognostic factor in esophageal cancer.
    Sadot E; Kraus S; Stein M; Naboishchikov I; Toledano O; Kazanov D; Arber N; Kashtan H
    Int J Biol Markers; 2014 Mar; 29(1):e49-54. PubMed ID: 24474454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
    Ingles SA; Ross RK; Yu MC; Irvine RA; La Pera G; Haile RW; Coetzee GA
    J Natl Cancer Inst; 1997 Jan; 89(2):166-70. PubMed ID: 8998186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis.
    Diaz-Gallo LM; Medrano LM; Gómez-García M; Cardeña C; Rodrigo L; Mendoza JL; Taxonera C; Nieto A; Alcain G; Cueto I; López-Nevot MA; Urcelay E; Martin J
    Hum Immunol; 2011 Oct; 72(10):969-72. PubMed ID: 21684315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of interleukin-6 gene polymorphisms in the development of prostate cancer.
    Chen CH; Gong M; Yi QT; Guo JH
    Genet Mol Res; 2015 Oct; 14(4):13370-4. PubMed ID: 26535651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population.
    Albayrak S; Cangüven O; Göktaş C; Aydemir H; Köksal V
    Urol Int; 2007; 79(4):312-5. PubMed ID: 18025848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
    Sun T; Mary LG; Oh WK; Freedman ML; Pomerantz M; Pienta KJ; Kantoff PW
    Clin Cancer Res; 2011 Mar; 17(6):1546-52. PubMed ID: 21135144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects.
    Zhang K; Chen X; Zhou J; Yang C; Zhang M; Chao M; Zhang L; Liang C
    Oncotarget; 2017 Jul; 8(27):45020-45029. PubMed ID: 28445160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
    Sun J; Wiklund F; Hsu FC; Bälter K; Zheng SL; Johansson JE; Chang B; Liu W; Li T; Turner AR; Li L; Li G; Adami HO; Isaacs WB; Xu J; Grönberg H
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):480-5. PubMed ID: 16537705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
    Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
    Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.